Oxolife Appoints International Fertility Experts to its Scientific Advisory Board
- Leading experts in fertility and human reproduction with more than 1,200 fertility and reproduction-related publications
- SAB involved in the clinical management at top global reproductive clinics and research centers worldwide
- Support plans to advance clinical development of OXO-001, a novel first in class treatment for infertility
Barcelona, Spain – 13th November 2023, Oxolife, the specialist biotech focused on enhancing embryo implantation in women undergoing Assisted Reproductive Technology (ART) fertility treatment, today announces it has appointed globally renowned fertility experts to its Scientific Advisory Board (SAB).
